Quest to Offer Septin9 Colorectal Cancer LTD 'Later This Year'

Epigenomics, on whose mSEPT9 DNA-methylation biomarker the test will be based, said Quest has finished clinically validating the test, which has triggered an undisclosed milestone payment from the reference lab.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories

What are the real benefits of

What are the real benefits of the test? How early can it find the the cancer? Is it life saving? There are a lot of questions that need to be answered. I welcome the test, I am sure it will meed all of our hopes. Are hemroids signs of an early stage of rectal cancer?

Has this test been released

Has this test been released yet? If so how effective is it at detecting colorectal cancer and can it also prevent hemorrhoids?